Recursion Pharmaceuticals announced the top-line results of its SYCAMORE trial for REC-994 in patients with cerebral cavernous malformation and provided financial information regarding its proposed acquisition of Exscientia, which is expected to resu
AI Assistant
RECURSION PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.